Completed
CTNPT 052: Glycoprotein 120 as a pan-toxin
Exploring the role of the soluble glycoprotein 120 as a pan-toxin driving immune dysfunction and accelerated aging in people living with HIV
Learn MoreCompleted
Exploring the role of the soluble glycoprotein 120 as a pan-toxin driving immune dysfunction and accelerated aging in people living with HIV
Learn MoreEnrolling
Discovering pathways to successful aging in people living with HIV
Learn MoreOngoing
Determinants of Increased Risk of Cardiovascular Diseases in Individuals Living with HIV
Learn MoreCTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.